NCT00054431View on ClinicalTrials.gov

Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

May 31, 2007

Conditions
Accelerated Phase Chronic Myelogenous LeukemiaBlastic Phase Chronic Myelogenous LeukemiaChildhood Chronic Myelogenous LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 PositiveRelapsing Chronic Myelogenous Leukemia
Interventions
DRUG

imatinib mesylate

Given orally

DRUG

decitabine

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00054431 - Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia | Biotech Hunter | Biotech Hunter